Comparison of various clinical parameters in MDS cohort with presence or absence of CM. Total white count and AMC were more likely to be higher in the MDS cohort with CM when compared with the subgroup of MDS without presence of CM. Furthermore, patients in the MDS cohort who did not have CM were likely to have high-risk disease as determined by IPSS-R, and were likely to have poor-risk cytogenetics. SF3B1 mutations were found in greater frequency in the MDS cohort with presence of CM compared with the MDS subgroup with absence of CM (OR, 3.706; 95% CI, 1.117-12.26; P = .04). ALC, absolute lymphocyte count; ECOG, Eastern Cooperative Oncology Group; IPSS-R, revised International Prognostic Scoring System; PRBCs, packed red blood cells.